Why Cell Therapy Needs a Digital Backbone - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Why Cell Therapy Needs a Digital Backbone

Alexander Seyf on why the UK is losing ground in cell and gene therapy, the real bottlenecks to commercialization, and why digitalization is no longer optional

  • August 13, 2026

  • 8 min

Share

  • 1

    Alexander Seyf emphasizes the need for digital platforms to scale cell and gene therapy production beyond individual patient treatment.

  • 2

    The UK has lost momentum in cell and gene therapy compared to Europe and Asia, partly due to Brexit and reduced government focus.

  • 3

    Collaboration and information sharing are critical bottlenecks in the cell and gene therapy ecosystem, hindering progress.

  • 4

    California's California Institute for Regenerative Medicine exemplifies effective collaboration, supporting biotech growth.

  • 5

    Digitalization is viewed as essential for overcoming inefficiencies and enhancing scalability in cell therapy manufacturing.

Original Source(s)

Why Cell Therapy Needs a Digital Backbone

  • August 13, 2026

Related Content

How Often Is Thyroid Hormone Needed After Hemithyroidectomy?

Nearly 40% of patients initiated thyroid hormone therapy within 2 years of hemithyroidectomy, with higher preoperative thyroid‐stimulating hormone levels and thyroid cancer identifying those at greatest risk.

Redefining Fontan Care: The Socio-Economic Impact of SVHD on Families

Survey results reveal the long-term socio-economic and psychological impacts of single ventricle congenital heart disease (SVHD) on families. See how cardiologists Deepti Bhat, MD, and Naim Duran, MD, contributors to this research, are using findings to transform Fontan Clinic care at Phoenix Children’s.

  • by

  • August 12, 2026

  • 6 min
Product Labels Miss Hidden Chemicals

Testing found that nearly 60% of top-rated "Go" products failed contamination testing.